Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study

Adele de Masson; Marie Beylot-Barry; Caroline Ram-Wolff; Jean-Baptiste Mear; Stephane Dalle; Jacques Rouanet; Saskia Ingen-Housz-Oro; Corentin Orvain; Julie Abraham; Olivier Dereure; Amandine Charbonnier; Jerome Cornillon; Christine Longvert; Stephane Barete; Serge Boulinguez; Ewa Wierzbicka-Hainaut; Francois Aubin; Marie-Therese Rubio; Marc Bernard; Aline Schmidt-Tanguy; Roch Houot; Anne Pham-Ledard; David Michonneau; Helene Labussiere-Wallet; Jean-David Bouaziz; Florent Grange; Helene Moins-Teisserenc; Katayoun Jondeau; Samia Mourah; Maxime Battistella; Etienne Daguindau; Michael Loschi; Alexandra Picard; Nathalie Franck; Natacha Maillard; Anne Huynh; Stephanie Nguyen; Ambroise Marcais; Guillaume Chaby; Patrice Ceballos; Yannick Le Corre; Sebastien Maury; Jacques-Olivier Bay; Henri Adamski; Emmanuel Bachy; Edouard Forcade; Gerard Socie; Martine Bagot; Sylvie Chevret; Regis Peffault de Latour; on behalf of CUTALLO Investigators, Groupe Français d’Etude des Lymphomes Cutanés and Société Française de Greffe de Moëlle et Thérapie Cellulaire

doi:10.1200/JCO-25-00183

Retour

Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study

Article de revue

Avec comité de lecture

Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study

Adele de Masson, Marie Beylot-Barry, Caroline Ram-Wolff, Jean-Baptiste Mear, Stephane Dalle, Jacques Rouanet, Saskia Ingen-Housz-Oro, Corentin Orvain, Julie Abraham, Olivier Dereure, …

Journal of clinical oncology, Vol.43(22), pp.2461-2466

01/08/2025

DOI: https://doi.org/10.1200/JCO-25-00183

PMID: 40513043

Résumé

Life Sciences & Biomedicine

Oncology

Science & Technology

Cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and sometimes fatal diseases. Patients presenting with advanced-stage CTCL usually exhibit poor long-term survival outcomes. Only very few treatments have improved progression-free survival (PFS) in advanced CTCL, and no treatment has increased overall survival (OS). In 2023, the results of the CUTALLO trial supported the hypothesis that hematopoietic stem-cell transplantation (HSCT) was associated with significantly longer PFS as compared with standard-of-care treatment among advanced-stage patients although HSCT did not significantly affect OS. We provide herein the final OS data pertaining to the same patient population after a longer median follow-up of 38.9 months. Of the 99 patients included in the analysis, 55 (56%) were assigned to the HSCT group, whereas 44 (44%) were allocated to the non-HSCT group. The updated survival analysis reported that 16 of 55 patients (29%) in the HSCT group and 22 of 44 patients (50%) in the non-HSCT group died. The median OS was not reached in the HSCT group and 51.5 months (95% CI, 26.9 to 51.5) in the non-HSCT group (hazard ratio, 0.40 [95% CI, 0.20 to 0.80]). Compared with the standard of care for advanced CTCL, after extended follow-up, allogeneic HSCT was associated with significantly longer OS.

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study
Créateurs - sans rôle: Adele de Masson - St Louis Hosp, Dept Dermatol, AP HP, Paris, France
Marie Beylot-Barry - CHU Bordeaux, Dept Dermatol, Bordeaux, France
Caroline Ram-Wolff - Assistance Publique – Hôpitaux de Paris
Jean-Baptiste Mear - Centre Hospitalier Universitaire de Rennes
Stephane Dalle - Hop Lyon Sud, Dept Dermatol, Lyon, France
Jacques Rouanet - CHU Clermont Ferrand, Dept Dermatol, Clermont Ferrand, France
Saskia Ingen-Housz-Oro - Univ Paris Est Creteil, Hop Henri Mondor, Dept Dermatol, AP HP, Creteil, France
Corentin Orvain - CHU Angers, Dept Hematol, Angers, France
Julie Abraham - CHU Limoges, Dept Hematol, Limoges, France
Olivier Dereure - Univ Montpellier, Dept Dermatol, Montpellier, France
Amandine Charbonnier - CHU Amiens, Dept Hematol, Amiens, France
Jerome Cornillon - CHU St Etienne, Dept Clin Hematol & Cellular Therapy, St Etienne, France
Christine Longvert - CHU Ambroise Pare, Dept Dermatol, AP HP, Boulogne Billancourt, France
Stephane Barete - Assistance Publique – Hôpitaux de Paris
Serge Boulinguez - CHU Toulouse, Dept Dermatol, Toulouse, France
Ewa Wierzbicka-Hainaut - CHU Poitiers, Dept Dermatol, Poitiers, France
Francois Aubin - CHU Besancon, Dept Dermatol, Besancon, France
Marie-Therese Rubio - CHRU Nancy, Hop Brabois, Dept Hematol, Nancy, France
Marc Bernard - Centre Hospitalier Universitaire de Rennes
Aline Schmidt-Tanguy - CHU Angers, Dept Hematol, Angers, France
Roch Houot - Univ Rennes, Dept Hematol, CHU Rennes, INSERM, Rennes, France
Anne Pham-Ledard - CHU Bordeaux, Dept Dermatol, Bordeaux, France
David Michonneau - INSERM U1342 Inst Rech St Louis, Paris, France
Helene Labussiere-Wallet - Hosp Civils Lyon, Hosp Lyon Sud, Pierre Benite, France
Jean-David Bouaziz - Assistance Publique – Hôpitaux de Paris
Florent Grange - Ctr Hosp Valence, Dept Dermatol, Valence, France
Helene Moins-Teisserenc - Univ Paris Cite, Paris, France
Katayoun Jondeau - CHU Ambroise Pare, Dept Hematol, AP HP, Boulogne Billancourt, France
Samia Mourah - Institut de recherche Saint-Louis
Maxime Battistella - Institut de recherche Saint-Louis
Etienne Daguindau - CHU Besancon, Dept Hematol, Besancon, France
Michael Loschi - Ctr Hosp Univ Nice, Hop Archet, Dept Hematol, Nice, France
Alexandra Picard - CHU Nice, Dept Dermatol, Nice, France
Nathalie Franck - Assistance Publique – Hôpitaux de Paris
Natacha Maillard - Centre Hospitalier Universitaire de Poitiers
Anne Huynh - CHU Toulouse, Dept Hematol, IUCT Oncopole, Toulouse, France
Stephanie Nguyen - CHU Pitie Salpetriere, Dept Hematol, AP HP, Paris, France
Ambroise Marcais - CHU Necker, Dept Hematol, AP HP, Paris, France
Guillaume Chaby - CHU Amiens, Dept Dermatol, Amiens, France
Patrice Ceballos - CHU Montpellier, Dept Hematol, Montpellier, France
Yannick Le Corre - Centre Hospitalier Universitaire d'Angers
Sebastien Maury - Centre Hospitalier Universitaire Henri-Mondor
Jacques-Olivier Bay - CHU Clermont Ferrand, Dept Hematol, Clermont Ferrand, France
Henri Adamski - CHU Rennes, Hop Pontchaillou, Dept Dermatol, Rennes, France
Emmanuel Bachy - CHU Lyon, Dept Hematol, Lyon, France
Edouard Forcade - CHU Bordeaux, Dept Clin Hematol & Cellular Therapy, Bordeaux, France
Gerard Socie - Institut de recherche Saint-Louis
Martine Bagot - Assistance Publique – Hôpitaux de Paris
Sylvie Chevret - Univ Paris Cite, Paris, France
Regis Peffault de Latour - Univ Paris Cite, Paris, France
on behalf of CUTALLO Investigators, Groupe Français d’Etude des Lymphomes Cutanés and Société Française de Greffe de Moëlle et Thérapie Cellulaire
Détails de publication: Journal of clinical oncology, Vol.43(22), pp.2461-2466
Éditeur: Lippincott Williams & Wilkins
Nombre de pages: 6
Note de subvention: PHRC-K 2014 / French National Cancer Institute; Institut National du Cancer (INCA) France Good Publications Practice 3 guidelines
Identifiants: 99157079309311
Unité académique: Pathogenesis and Control of Chronic and Emerging Infections - PCCEI
Langue: English
Type de ressource: Journal article